Progestin-only treatments for acute and chronic heavy menstrual bleeding

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

AL Nelson is supported by grants from Bayer, Merck, Pfizer and Teva. She is a consultant or on the advisory board for Agile, Bayer, Merck, Teva and Watson and has received honoraria from Bayer, Merck and Teva. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.